We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | 장 마감 후 (AMC) | $-0.01 | — | — | $48.61M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | — | — | — | $41.46M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | — | — | — | $142.98M |
Consensus PT $5.69 · 4 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Stephens & Co. | — | 의견 유지 | Overweight → Overweight | — | Stephens & Co.: Overweight |
| 2026. 05. 13. | Morgan Stanley | — | 의견 유지 | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | — | — | — | $91.48M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 114,256 | $576.99M | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 30,032 | $151.66M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Stored first · Google News · Yahoo Finance (English)
Promising Penny Stocks To Consider In June 2026
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 Moomoo
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming - Moomoo
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming Moomoo
Cytek Biosciences stock (US23284C1053): insider RSU activity keeps focus on growth story - AD HOC NEWS
Cytek Biosciences stock (US23284C1053): insider RSU activity keeps focus on growth story AD HOC NEWS
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock Stock Titan